TOP TEN perturbations for 39056_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39056_at
Selected probe(set): 201013_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39056_at (201013_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):4.2147293Number of Samples:2 / 2
Experimental | T-cell activation study 4 |
T-cell samples antiCD3 activated for 30hrs. | |
Control | normal resting T-cell sample |
T cells resting for 30h. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-3.8816853Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.787754Number of Samples:3 / 3
Experimental | glioma study 17 (glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):-3.5605688Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
hCMV study 1 (CD69+) / uninfected CD4 T-LGL sample (diseased)
Relative Expression (log2-ratio):3.4743204Number of Samples:4 / 3
Experimental | hCMV study 1 (CD69+) |
CD69+ human cytomegalovirus (hCMV)-stimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis. | |
Control | uninfected CD4 T-LGL sample (diseased) |
Unstimulated monoclonal CD4+ T-large granular lymphocytes (T-LGL) from peripheral blood of patients with monoclonal T-cell receptor (TCR)-alphabeta(+)/CD4(+) T-large granular lymphocyte (LGL) lymphocytosis. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):3.3963604Number of Samples:2 / 2
Experimental | T-cell activation study 3 |
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
Control | resting CD4 T-lymphocyte (crude fraction) sample |
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-3.3715658Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):3.295826Number of Samples:2 / 2
Experimental | T-cell activation study 1 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):3.2126217Number of Samples:2 / 2
Experimental | T-cell activation study 2 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
memory T-cell activation study 1 / untreated memory CD4 T-cell sample
Relative Expression (log2-ratio):2.9066763Number of Samples:3 / 3
Experimental | memory T-cell activation study 1 |
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. | |
Control | untreated memory CD4 T-cell sample |
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation. |